Table 1.
Patients’ demographic and baseline clinical characteristics (n = 89)
| Characteristic | Count (%) |
|---|---|
| Gender, n (%) | |
| Male | 45 (49) |
| Female | 44 (51) |
| Age, n (%) | |
| < 60 years | 57 (64) |
| ≥ 60 years | 32 (36) |
| Race, n (%) | |
| Non-Hispanic White | 63 (71) |
| African-American | 18 (20) |
| Hispanic | 8 (9) |
| Performance status, n (%) | |
| 0 | 35 (39) |
| 1 | 49 (55) |
| 2 | 5 (6) |
| Histological grade | |
| Well | 3 (3) |
| Moderate | 69 (78) |
| Poor | 17 (19) |
| Number of metastatic sites | |
| < 3 | 42 (47) |
| ≥ 3 | 47 (53) |
| Serum albumin | |
| Normal | 72 (81) |
| Low (<3.5 g/dL) | 17 (19) |
| Serum LDH | |
| Normal | 19 (21) |
| Elevated (>618 IU/L) | 70 (79) |
| RMH Score | |
| < 2 | 43 (48) |
| ≥ 2 | 46 (52) |
| KRAS exon 2 wild-typea | 89 (100) |
| KRAS non-exon 2 mutations (n = 70) | 0 |
| NRAS mutations (n = 23) | 0 |
| BRAF V600E mutation (n = 64) | 0 |
| PIK3CA mutations (n = 37) | 6 |
aKRAS exon 2 wild-type status included codons 12 and 13 (exon 2); non-exon 2 KRAS mutations included exon 3 in 55 cases and exon 3 + 4 in 15 cases; NRAS mutations included exons 2 in 23, exon 3 in 17 and exon 4 in 6; PIK3CA mutations included hotspots within exons 9 and 20